Vanguard Personalized Indexing Management LLC Grows Stock Position in Alector, Inc. $ALEC

Vanguard Personalized Indexing Management LLC boosted its stake in Alector, Inc. (NASDAQ:ALEC) by 49.2% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 52,095 shares of the company’s stock after buying an additional 17,170 shares during the quarter. Vanguard Personalized Indexing Management LLC owned approximately 0.05% of Alector worth $73,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of ALEC. Vontobel Holding Ltd. lifted its stake in shares of Alector by 26.7% during the second quarter. Vontobel Holding Ltd. now owns 38,000 shares of the company’s stock valued at $53,000 after buying an additional 8,000 shares during the period. Jane Street Group LLC raised its holdings in Alector by 4.7% in the 1st quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock valued at $316,000 after acquiring an additional 11,618 shares during the last quarter. ADAR1 Capital Management LLC raised its holdings in Alector by 3.3% in the 1st quarter. ADAR1 Capital Management LLC now owns 380,330 shares of the company’s stock valued at $468,000 after acquiring an additional 12,000 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Alector by 8.1% during the 1st quarter. Bank of New York Mellon Corp now owns 249,494 shares of the company’s stock worth $307,000 after purchasing an additional 18,765 shares during the period. Finally, CWM LLC boosted its holdings in shares of Alector by 370.7% during the first quarter. CWM LLC now owns 33,643 shares of the company’s stock worth $41,000 after purchasing an additional 26,495 shares during the last quarter. Institutional investors and hedge funds own 85.83% of the company’s stock.

Insider Buying and Selling at Alector

In other Alector news, Director Paula Hammond sold 14,000 shares of the stock in a transaction on Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total value of $33,040.00. Following the sale, the director directly owned 74,909 shares of the company’s stock, valued at $176,785.24. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 9.70% of the company’s stock.

Alector Stock Performance

Shares of ALEC opened at $1.50 on Monday. The firm has a market cap of $151.82 million, a price-to-earnings ratio of -1.29 and a beta of 0.99. The company has a quick ratio of 3.78, a current ratio of 3.78 and a debt-to-equity ratio of 0.13. The business’s 50 day moving average is $2.77 and its two-hundred day moving average is $1.90. Alector, Inc. has a 52-week low of $0.87 and a 52-week high of $6.14.

Alector (NASDAQ:ALEC) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The business had revenue of $7.87 million during the quarter, compared to the consensus estimate of $2.76 million. Alector had a negative return on equity of 112.06% and a negative net margin of 142.10%. Alector has set its FY 2025 guidance at EPS. Analysts forecast that Alector, Inc. will post -1.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ALEC. BTIG Research downgraded shares of Alector from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. Mizuho set a $1.50 price target on shares of Alector and gave the stock a “neutral” rating in a research note on Wednesday. TD Cowen lowered shares of Alector from a “buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Alector in a report on Friday. Finally, HC Wainwright cut their target price on Alector from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a Buy rating, seven have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Alector presently has a consensus rating of “Reduce” and a consensus price target of $3.00.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.